Dapsone 5 gel: A review of its efficacy and safety in the treatment of acne vulgaris

American Journal of Clinical Dermatology

Volumn 10, Issue 4, 2009, Pages 221-227

  Stotland, Mira ^a   Shalita, Alan R ^a   Kissling, Robert F ^b  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

^b QLT Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLDAPSONE; ACZONE; COTRIMOXAZOLE; DAPSONE; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; HEMOGLOBIN; UNCLASSIFIED DRUG;

ACNE; ACNE VULGARIS; ANTIINFLAMMATORY ACTIVITY; APPLICATION SITE DRYNESS; APPLICATION SITE ERYTHEMA; APPLICATION SITE REACTION; AREA UNDER THE CURVE; CLINICAL TRIAL; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; GEL; HEADACHE; HEMOLYSIS; HUMAN; MAXIMUM PLASMA CONCENTRATION; PRIORITY JOURNAL; REVIEW; RHINOPHARYNGITIS; TOPICAL TREATMENT;

ACNE VULGARIS; ADMINISTRATION, CUTANEOUS; ANTI-INFECTIVE AGENTS; CLINICAL TRIALS AS TOPIC; DAPSONE; DERMATOLOGIC AGENTS; GELS; HUMANS; TREATMENT OUTCOME;

EID: 67650484916     PISSN: 11750561     EISSN: 11791888     Source Type: Journal    
DOI: 10.2165/00128071-200910040-00002     Document Type: Review

References (17)

1. White GM. Recent findings in the epidemiologic evidence, classification, and subtypes of acne vulgaris. J Am Acad Dermatol 1998; 39 Suppl.: S34-7
2. American Academy of Dermatology Public Resource Center. Acne [online]. Available at URL: http://www.aad.org/public/publications/pamphlets/acne. htm [Accessed 2008 Oct 10]
3. Lasek RJ, Chren M-M. Acne vulgaris and the quality of life of adult derma tology patients. Arch Dermatol 1998; 143: 454-8
4. Harper JC, Thiboutot DM. Pathogenesis of acne: recent research advances. Adv Dermatol 2003; 19: 1-10
5. Jeremy AH, Holland DB, Roberts SG, et al. Inflammatory events are involved in acne lesion initiation. J Invest Dermatol 2003; 121: 20-7
6. Gollnick H, Cunliffe W, Berson D, et al. Management of acne: a report from a Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol 2003; 49 (1 Suppl.): S1-37
7. Zhu YI, Stiller MJ. Dapsone and sulfones in dermatology: overview and update. J Am Acad Dermatol 2001; 45: 420-34
8. Ross CM. The treatment of acne vulgaris with dapsone. Br J Dermatol 1961; 73: 367-70
9. Kaminsky A. Less common methods to treat acne. Dermatology 2003; 206: 68-73
10. Draelos ZD, Carter E, Maloney JM, et al. Two randomized studies demon strate the efficacy and safety of dapsone gel, 5% for the treatment of acne vulgaris. J Am Acad Dermatol 2007; 56: 439-47
11. Lucky AW, Maloney JM, Roberts J, et al. Dapsone gel 5% for the treatment of acne vulgaris: safety and efficacy of long-term (1 year) treatment. J Drugs Dermatol 2007; 6: 981-7
12. Thiboutot DM, Willmer J, Sharata H, et al. Pharmacokinetics of dapsone gel, 5% for the treatment of acne vulgaris. J Clin Pharmacokinet 2007; 46: 697-712
13. Dapsone prescribing information. Princeton (NJ): Jacobus Pharmaceutical Co., Inc., 1997
14. Cunliffe WJ, Poncet M, Loesche C, et al. A comparison of the efficacy and tolerability of adapalene 0.1% gel versus tretinoin 0.025% gel in patients with acne vulgaris: a meta-analysis of five randomized trials. Br J Dermatol 1998; 139 Suppl. 52: 48-56
15. Benzaclin topical gel (clindamycin-benzoyl peroxide gel) [package insert]. Benwyn (PA): Dermik Laboratories (a division of Aventis Pharmaceuticals, Inc.), 2003 Sep
16. Duac topical gel (clindamycin, 1% benzoyl peroxide, 5%) [package insert]. Coral Gables (FL): Stiefel Laboratories, Inc., 2003 Nov
17. Piette WW, Taylor S, Pariser D, et al. Hematologic safety of dapsone gel, 5%, for topical treatment of acne vulgaris. Arch Dermatol 2008 Dec; 144 (12): 1564-70